Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ablynx Opens New R&D Facility
Ablynx is developing a nanobody-based portfolio of therapeutics in a number of therapeutic areas, including inflammation, thrombosis, oncology and Alzheimer’s disease. Ablynx has over 25 programmes in its
Ablynx is developing a nanobody-based portfolio of therapeutics in a number of therapeutic areas, including inflammation, thrombosis, oncology and Alzheimer’s disease. Ablynx has over 25 programmes in its
Dr Amphlett and Dr Lutz have played central roles in establishing ImmunoGen’s product development capabilities. These functions complement the company’s research capabilities in ImmunoGen’s advancement of its own
The new facility is expected to allow OvaGene Oncology to perform genomic testing on cancer cells using advanced technologies such as Quantitative Polymerase Chain Reaction (QPCR), Comparative Genomic
The various aspects evaluated during the inspection include line production, laboratory safety, production control, inventory logistics on over 100 products, upkeep of the physical property, and proper management
Kendle claimed that the new SEZ operations center integrates all the clinical support services which focus on delivery of clinical data management, medical writing, pharmacovigilance/safety, biostatistics/programming and other
Dapagliflozin, an investigational compound, is a potential sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers Squibb Company and AstraZeneca. The study also
Eribulin is an investigational anticancer agent discovered and developed by Eisai. Eisai filed simultaneous regulatory applications for approval of Eribulin to the health authorities in the US, Japan
GSK and Medivir claimed that Xerclear is the first and only topical herpes labialis (cold sores) treatment clinically proven to help prevent cold sore lesions appearing. As per
The study was designed to allow US based investigators and the FDA to evaluate Rigerimod (Lupuzor) as a treatment for lupus before commencing a Phase III clinical trial.
The two new programs added are expected to address the development of four compounds which target different subpopulations of patients suffering from DMD. To access these new programs,